FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138441674> ?p ?o ?g. }

• W2138441674 endingPage "1559" @default.
• W2138441674 startingPage "1533" @default.
• W2138441674 abstract "Despite its clinical and histological heterogeneity, anaplastic large cell lymphoma (ALCL) is now a well-recognized clinicopathological entity accounting for 2% of all adult non-Hodgkin's lymphomas (NHL) and about 13% of pediatric NHL. Immunophenotypically, ALCL are of T cell (predominantly) or Null cell type; by definition, cases expressing B cell antigens are officially not included in this entity. The translocation (2;5)(p23;q35) is a recurring abnormality in ALCL; 46% of the ALCL patients bear this signature translocation. This translocation creates a fusion gene composed of nucleophosmin (NPM) and a novel receptor tyrosine kinase gene, named anaplastic lymphoma kinase (ALK). The NPM-ALK chimeric gene encodes a constitutively activated tyrosine kinase that has been shown to be a potent oncogene. The exact pathogenetic mechanisms leading to lymphomagenesis remain elusive; however, the synopsis of evidence obtained to date provides an outline of likely scenarios. Several t(2;5) variants have been described; in some instances, the breakpoints have been cloned and the genes forming a new fusion gene with ALK have been identified: ATIC-ALK, TFG-ALK and TPM3-ALK. Cloning the translocation breakpoint and identifying the ALK and NPM genes provided tools for screening material from patients with ALCL using various approaches at the chromosome, DNA, RNA, or protein level: positive signals in the reverse transcriptase-polymerase chain reaction (RT-PCR) and the immunostaining with anti-ALK monoclonal antibodies (McAb) serve as the most convenient tests for detection of the t(2;5) NPM-ALK since the fusion gene and ALK protein expression do not occur in normal or reactive lymphoid tissue. The wide range of NPM-ALK positivity reported in different series appears to be dependent on the inclusion and selection criteria of the ALCL cases studied. Overall, however, 43% of ALCL cases were NPM-ALK+ (83% of pediatric ALCL vs 31% of adult ALCL). Occasional non-ALCL B cell lymphomas (4%) with diffuse large cell and immunoblastic histology and Hodgkin's disease cases (3%) were NPM-ALK-, but these data are questionable. The aggregate results indicate that, in contrast to primary nodal (systemic) ALCL, the t(2;5) may be present in only 10-20% of primary cutaneous ALCL and rarely, if at all, in lymphomatoid papulosis, a potential precursor lesion; however, these 10-20% positive cases were not confirmed by anti-ALK McAb immunostaining and may represent an overestimate. Positivity for NPM-ALK is associated to various degrees with the following parameters: 44% and 45% of ALCL cases with T cell and Null cell immunophenotype, respectively, are positive, whereas only 8% of cases with a B cell immunoprofile are positive; the mean age of positive patients is significantly younger than that of negative patients; positive cases carry a better overall prognosis (but not in all studies). Recently, the homogenous category of ALK lymphoma ('ALKoma') has emerged as a distinct pathological entity within the heterogenous group of ALCL. The fact that patients with ALK lymphomas experience significantly better overall survival than ALK- ALCL demonstrates further that analysis of ALK expression has important prognostic implications. The term ALK lymphoma signifies a switch in the use of the diagnostic criteria: cases are selected on the basis of a genetic abnormality (the ALK rearrangement), instead of the review of morphological or immunophenotypical features which are clearly more prone to disagreement and controversy. Since its initial description in 1985 ALCL has become one of the best characterized lymphoma entities." @default.
• W2138441674 created "2016-06-24" @default.
• W2138441674 creator A5008615346 @default.
• W2138441674 creator A5028192601 @default.
• W2138441674 creator A5041495085 @default.
• W2138441674 creator A5055778036 @default.
• W2138441674 creator A5057584755 @default.
• W2138441674 date "2000-08-31" @default.
• W2138441674 modified "2023-10-18" @default.
• W2138441674 title "Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas" @default.
• W2138441674 cites W1028569293 @default.
• W2138441674 cites W117807078 @default.
• W2138441674 cites W126560450 @default.
• W2138441674 cites W129140633 @default.
• W2138441674 cites W1426751272 @default.
• W2138441674 cites W1488086007 @default.
• W2138441674 cites W1488754274 @default.
• W2138441674 cites W149221749 @default.
• W2138441674 cites W1500415400 @default.
• W2138441674 cites W1500807433 @default.
• W2138441674 cites W1519176158 @default.
• W2138441674 cites W1520668050 @default.
• W2138441674 cites W1525811283 @default.
• W2138441674 cites W1534155209 @default.
• W2138441674 cites W153432272 @default.
• W2138441674 cites W1536108064 @default.
• W2138441674 cites W1543500536 @default.
• W2138441674 cites W1549526024 @default.
• W2138441674 cites W1553544241 @default.
• W2138441674 cites W1554739819 @default.
• W2138441674 cites W1562875840 @default.
• W2138441674 cites W1586739835 @default.
• W2138441674 cites W1599349966 @default.
• W2138441674 cites W1676096827 @default.
• W2138441674 cites W1745574033 @default.
• W2138441674 cites W1785998771 @default.
• W2138441674 cites W180574079 @default.
• W2138441674 cites W1850002090 @default.
• W2138441674 cites W1900846547 @default.
• W2138441674 cites W1921834202 @default.
• W2138441674 cites W1922967872 @default.
• W2138441674 cites W1949104778 @default.
• W2138441674 cites W1965691420 @default.
• W2138441674 cites W1967778754 @default.
• W2138441674 cites W1969851734 @default.
• W2138441674 cites W1969889989 @default.
• W2138441674 cites W1970920717 @default.
• W2138441674 cites W1971827703 @default.
• W2138441674 cites W1973258898 @default.
• W2138441674 cites W1979366214 @default.
• W2138441674 cites W1982153061 @default.
• W2138441674 cites W1985143320 @default.
• W2138441674 cites W1985477550 @default.
• W2138441674 cites W1986168173 @default.
• W2138441674 cites W1986954124 @default.
• W2138441674 cites W1992587761 @default.
• W2138441674 cites W1992764943 @default.
• W2138441674 cites W1992769898 @default.
• W2138441674 cites W1993605768 @default.
• W2138441674 cites W1993719557 @default.
• W2138441674 cites W1994835972 @default.
• W2138441674 cites W1997300076 @default.
• W2138441674 cites W1998249611 @default.
• W2138441674 cites W1999416593 @default.
• W2138441674 cites W2000371328 @default.
• W2138441674 cites W2000777699 @default.
• W2138441674 cites W2001833692 @default.
• W2138441674 cites W2003587204 @default.
• W2138441674 cites W2003709346 @default.
• W2138441674 cites W2004030089 @default.
• W2138441674 cites W2005675973 @default.
• W2138441674 cites W2007938901 @default.
• W2138441674 cites W2008329190 @default.
• W2138441674 cites W2009474311 @default.
• W2138441674 cites W2011471498 @default.
• W2138441674 cites W2011636814 @default.
• W2138441674 cites W2012828375 @default.
• W2138441674 cites W2015756326 @default.
• W2138441674 cites W2016948320 @default.
• W2138441674 cites W2018007588 @default.
• W2138441674 cites W2018118917 @default.
• W2138441674 cites W2018829699 @default.
• W2138441674 cites W2020727809 @default.
• W2138441674 cites W2023757019 @default.
• W2138441674 cites W2025635508 @default.
• W2138441674 cites W2026002143 @default.
• W2138441674 cites W2026150272 @default.
• W2138441674 cites W2026418779 @default.
• W2138441674 cites W2027519886 @default.
• W2138441674 cites W2030560697 @default.
• W2138441674 cites W2031885800 @default.
• W2138441674 cites W2032359283 @default.
• W2138441674 cites W2033356999 @default.
• W2138441674 cites W2034960466 @default.
• W2138441674 cites W2035603442 @default.
• W2138441674 cites W2036754615 @default.
• W2138441674 cites W2038586807 @default.
• W2138441674 cites W2040457717 @default.

• next